Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

Exclusion criteria

• . For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. Serum pregnancy test to be performed at screening and urine pregnancy test to be performed prior to study treatment administration;
• . Subjects with history of breathing problems (i.e. history of asthma including childhood asthma);
• . Positive human immunodeficiency virus (HIV) 1 or HIV2 serology at screening;
• . Subject has pre-planned surgery or procedures that would interfere with the conduct of the study;
• . Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks, or complications from this disease, which has not resolved within 14 days prior to screening or prior to study treatment administration;
• . Blood donation or blood loss (≥ 450 mL) less than 2 months prior to screening or prior to study treatment administration;
• . Abnormal haemoglobin level defined as \< 13 g/dL for males and \< 11 g/dL for females at screening;
• . Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen evaluated at screening or prior to study treatment administration;